当前位置:首页 - 行情中心 - 华恒生物(688639) - 财务分析 - 现金流量表

华恒生物

(688639)

  

流通市值:89.67亿  总市值:89.67亿
流通股本:2.50亿   总股本:2.50亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,139,169,844.581,412,441,457.52648,660,311.452,323,340,962.09
  收到的税费返还78,172,268.5755,598,169.9625,589,077.8793,893,173.08
  收到其他与经营活动有关的现金35,578,875.0324,052,250.34,914,079.8146,354,143.52
  经营活动现金流入小计2,252,920,988.181,492,091,877.78679,163,469.132,463,588,278.69
  购买商品、接受劳务支付的现金1,717,363,072.231,130,890,211.75538,608,822.31,741,412,214.14
  支付给职工以及为职工支付的现金233,611,314.08154,930,521.2693,815,077.99270,733,005.97
  支付的各项税费47,546,495.1635,734,492.614,312,265.493,441,048.29
  支付其他与经营活动有关的现金139,658,595.7195,804,956.426,706,219.17158,207,398.66
  经营活动现金流出小计2,138,179,477.181,417,360,182.02663,442,384.862,263,793,667.06
  经营活动产生的现金流量净额114,741,51174,731,695.7615,721,084.27199,794,611.63
二、投资活动产生的现金流量:
  处置固定资产、无形资产和其他长期资产收回的现金净额37,856.717,558.7-367,445.21
  收到的其他与投资活动有关的现金--560,0003,247,706.83
  投资活动现金流入小计37,856.717,558.7560,0003,615,152.04
  购建固定资产、无形资产和其他长期资产支付的现金394,487,095.37253,699,111.4493,009,462.7923,510,013.72
  投资支付的现金---10,200,000
  支付其他与投资活动有关的现金10,002,257.877,751,377.872,090,000-
  投资活动现金流出小计404,489,353.24261,450,489.3195,099,462.7933,710,013.72
  投资活动产生的现金流量净额-404,451,496.54-261,432,930.61-94,539,462.7-930,094,861.68
三、筹资活动产生的现金流量:
  吸收投资收到的现金5,075,560.445,075,560.44-689,127,738.19
  取得借款收到的现金1,453,017,760.95792,207,827.21396,621,603.931,761,064,802.26
  筹资活动现金流入小计1,458,093,321.39797,283,387.65396,621,603.932,450,192,540.45
  偿还债务支付的现金990,237,333.19625,337,333.19311,437,333.191,471,406,681.37
  分配股利、利润或偿付利息支付的现金101,748,248.8922,397,131.999,884,947.29183,407,679.85
  支付其他与筹资活动有关的现金150,000--14,628,578.11
  筹资活动现金流出小计1,092,135,582.08647,734,465.18321,322,280.481,669,442,939.33
  筹资活动产生的现金流量净额365,957,739.31149,548,922.4775,299,323.45780,749,601.12
四、汇率变动对现金及现金等价物的影响1,745,348.31,463,668.066,481,912.6612,015,901.05
五、现金及现金等价物净增加额77,993,102.07-35,688,644.322,962,857.6862,465,252.12
  加:期初现金及现金等价物余额414,959,350.9414,959,350.9414,959,350.9352,494,098.78
  期末现金及现金等价物余额492,952,452.97379,270,706.58417,922,208.58414,959,350.9
补充资料:
  净利润-109,148,765.67-184,557,880.58
  资产减值准备-9,283,681.96-3,179,964.26
  固定资产和投资性房地产折旧-90,878,605.11-135,180,224.36
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-90,878,605.11-135,180,224.36
  无形资产摊销-2,777,323.29-3,476,610.57
  长期待摊费用摊销-2,535,438.33-934,630.12
  处置固定资产、无形资产和其他长期资产的损失-60,888.58-64,164.74
  固定资产报废损失-1,211,845.43-305,607.46
  财务费用-18,980,705.3-25,850,710.95
  投资损失-1,541,975.33--853,142.53
  递延所得税--15,057,860.67--6,717,501.73
  其中:递延所得税资产减少--20,719,497.63--37,144,423.46
    递延所得税负债增加-5,661,636.96-30,426,921.73
  存货的减少--111,323,784.44--181,096,316.29
  经营性应收项目的减少--38,925,797.58--58,418,008.6
  经营性应付项目的增加--4,484,194.76-85,664,509.34
  其他-3,881,707.55-8,745,700
  现金的期末余额-379,270,706.58-414,959,350.9
  减:现金的期初余额-414,959,350.9-352,494,098.78
  现金及现金等价物的净增加额--35,688,644.32-62,465,252.12
公告日期2025-10-282025-08-282025-04-232025-04-23
审计意见(境内)标准无保留意见
TOP↑